TY - JOUR
T1 - 2021 DORIS definition of remission in SLE
T2 - Final recommendations from an international task force
AU - van Vollenhoven, Ronald F.
AU - Bertsias, George
AU - Doria, Andrea
AU - Isenberg, David
AU - Morand, Eric
AU - Petri, Michelle A.
AU - Pons-Estel, Bernardo A.
AU - Rahman, Anisur
AU - Ugarte-Gil, Manuel Francisco
AU - Voskuyl, Alexandre
AU - Arnaud, Laurent
AU - Bruce, Ian N.
AU - Cervera, Ricard
AU - Costedoat-Chalumeau, Nathalie
AU - Gordon, Caroline
AU - Houssiau, Frédéric A.
AU - Mosca, Marta
AU - Schneider, Matthias
AU - Ward, Michael M.
AU - Alarcon, Graciela
AU - Aringer, Martin
AU - Askenase, Anka
AU - Bae, Sang-Cheol
AU - Bootsma, Hendrika
AU - Boumpas, Dimitrios T.
AU - Brunner, Hermine
AU - Clarke, Ann Elaine
AU - Coney, Cindy
AU - Czirják, L. szló
AU - Dörner, Thomas
AU - Faria, Raquel
AU - Fischer, Rebecca
AU - Fritsch-Stork, Ruth
AU - Inanc, Murat
AU - Jacobsen, S. ren
AU - Jayne, David
AU - Kuhn, Annegret
AU - van Leeuw, Bernadette
AU - Limper, Maarten
AU - Mariette, Xavier
AU - Navarra, Sandra
AU - Nikpour, Mandana
AU - Olesinska, Marzena Helena
AU - Pons-Estel, Guillermo
AU - Romero-Diaz, Juanita
AU - Rubio, Blanca
AU - Schoenfeld, Yehuda
AU - Bonfá, Eloisa
AU - Smolen, Josef
AU - Teng, Y. K. Onno
AU - Tincani, Angela
AU - Tsang-A-Sjoe, Michel
AU - Vasconcelos, Carlos
AU - Voss, Anne
AU - Werth, Victoria P.
AU - Zakharhova, Elena
AU - Aranow, Cynthia
N1 - Funding Information: Funding The DORIS Initiative was supported by unrestricted educational grants from Glaxo SmithKline and UCB Pharma. Publisher Copyright: © 2021 BMJ Publishing Group. All rights reserved.
PY - 2021/11/24
Y1 - 2021/11/24
N2 - Objective To achieve consensus on a definition of remission in SLE (DORIS). Background Remission is the stated goal for both patient and caregiver, but consensus on a definition of remission has been lacking. Previously, an international task force consisting of patient representatives and medical specialists published a framework for such a definition, without reaching a final recommendation. Methods Several systematic literature reviews were performed and specific research questions examined in suitably chosen data sets. The findings were discussed, reformulated as recommendations and voted on. Results Based on data from the literature and several SLE-specific data sets, a set of recommendations was endorsed. Ultimately, the DORIS Task Force recommended a single definition of remission in SLE, based on clinical systemic lupus erythematosus disease activitiy index (SLEDAI)=0, Evaluator’s Global Assessment <0.5 (0–3), prednisolone 5 mg/day or less, and stable antimalarials, immunosuppressives, and biologics. Conclusion The 2021 DORIS definition of remission in SLE is recommended for use in clinical care, education, and research including clinical trials and observational studies.
AB - Objective To achieve consensus on a definition of remission in SLE (DORIS). Background Remission is the stated goal for both patient and caregiver, but consensus on a definition of remission has been lacking. Previously, an international task force consisting of patient representatives and medical specialists published a framework for such a definition, without reaching a final recommendation. Methods Several systematic literature reviews were performed and specific research questions examined in suitably chosen data sets. The findings were discussed, reformulated as recommendations and voted on. Results Based on data from the literature and several SLE-specific data sets, a set of recommendations was endorsed. Ultimately, the DORIS Task Force recommended a single definition of remission in SLE, based on clinical systemic lupus erythematosus disease activitiy index (SLEDAI)=0, Evaluator’s Global Assessment <0.5 (0–3), prednisolone 5 mg/day or less, and stable antimalarials, immunosuppressives, and biologics. Conclusion The 2021 DORIS definition of remission in SLE is recommended for use in clinical care, education, and research including clinical trials and observational studies.
UR - http://www.scopus.com/inward/record.url?scp=85121234911&partnerID=8YFLogxK
U2 - https://doi.org/10.1136/lupus-2021-000538
DO - https://doi.org/10.1136/lupus-2021-000538
M3 - Review article
C2 - 34819388
SN - 2053-8790
VL - 8
JO - Lupus science & medicine
JF - Lupus science & medicine
IS - 1
M1 - e000538
ER -